Education
About Us
Working with TipRanks
Follow Us
iSpecimen (ISPC)
NASDAQ:ISPC
ISPC Stock Chart & Stats
$0.37
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.37
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$0.39 - $4.66
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$3.62M
Enterprise Value$2.15M
Total Cash (Recent Filing)$2.78M
Total Debt (Recent Filing)$281.44K
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Oct 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding9,771,028
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.20
P/FCF Ratio-0.23
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit2.97
Enterprise Value/Ebitda-0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $0.39 and its highest was $4.66 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $3.62M.
When is iSpecimen’s upcoming earnings report date?
iSpecimen’s upcoming earnings report date is Oct 30, 2025 which is 52 days ago.
How were iSpecimen’s earnings last quarter?
iSpecimen released its earnings results on Aug 12, 2025. The company reported -$0.419 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.419.
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 9,771,028 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
iSpecimen reported an EPS of -$0.419 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen (ISPC) is a technology-driven company that specializes in the procurement and supply of human biospecimens for research and clinical purposes. Operating at the intersection of healthcare and biotechnology, iSpecimen provides a platform that connects researchers and biopharma companies with a diverse and extensive network of biospecimen providers. The company focuses on accelerating medical research by offering a wide range of biospecimens, including blood, tissue, and urine samples, along with associated data, to facilitate studies in areas such as drug development, diagnostics, and personalized medicine.
Technical Analysis
Check-Cap
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.16% Mutual Funds
0.95% Other Institutional Investors
98.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---